Cambridge Heart, Inc. Release: Largest Prospective Study Of Microvolt T-Wave Alternans Demonstrates This Technology’s Predictive Value For Sudden Cardiac Death In Patients With Preserved Left Ventricular Function After Acute Myocardial Infarction

BEDFORD, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB-CAMH) announced today the publication of a study in the Journal of the American College of Cardiology assessing the utility of Microvolt T-Wave Alternans™ (MTWA) in predicting risk of sudden death among patients who have previously suffered a heart attack (Acute Myocardial Infarction; MI) yet have preserved cardiac function.